Satt Lutech Satt Lutech Satt Lutech

Contactez-nous 01 78 94 68 51

Vous souhaitez exploiter le projet

1/ Vos informations personnelles

2/ Vous souhaitez en savoir plus sur nos projets ou nous faire part de vos besoins/domaines d’intérêts

Précisez le(s) projet(s) innovant(s) qui vous intéressent : *


Lorem ipsum dolor sit amet, consectetur.

1/ Vos informations personnelles


Nom du fichier:

Taille du fichier:


Nom du fichier:

Taille du fichier:

New diagnostic tool to assess cardiovascular disease risk

Market challenges

Low levels of cholesterol carried by high-density lipoprotein (HDL) has an indisputable value as a predictor of elevated cardiovascular (CV) risk. As a consequence, HDL-cholesterol (HDL-C) concentration is present in all existing calculators of CV risk.
However, elevation of HDL-C levels using therapeutic approaches do not necessarily reduce CV risk. Indeed, patients with high levels of HDL-C might also be at risk for CV disease.
It has been suggested that CV risk is not reflected by HDL quantity, but rather by HDL function. Existing methods to evaluate HDL function do not however allow explaining excessive risk at high HDL-C levels.

Innovative solution

Team from Sorbonne Université has designed a new diagnostic tool to better assess cardiovascular disease risk associated with HDL.
The technology is based on the quantification of the HDL role in the lipolysis allowing to determine the key function of HDL reflecting CV risk.

Suggested applications

• Better evaluation of cardiovascular risk as compared to traditional measurement of HDL-C
• Prediction of cardiovascular risk in metabolic diseases
• Stratification of patients with cardiovascular disease

Development status

A validation tested case-control study is being performed on 120 plasma samples from a 10-year follow-up of subjects who subsequently developed CV disease.

Competitive advantages

• The diagnostic is simple and fast
• The test requires only minimal volumes of plasma
• The test improves evaluation of CV risk as compared to traditional lipid screening
• The test can better assess the efficiency of a treatment for CV disease.

Ce projet vous intéresse et vous souhaitez en savoir plus